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Abstract 1 
 2 
Background: Patient self-management plans (PSMP) are advised for bronchiectasis but 3 
their efficacy is not established. We aimed to determine whether, in people with 4 
bronchiectasis, the use of our bronchiectasis PSMP - Bronchiectasis Empowerment Tool 5 
(BET), compared to standard care, would improve self-efficacy. 6 
 7 
Methods: In a multi-centre mixed-methods randomised controlled parallel study, 220 8 
patients with bronchiectasis were randomised to receive standard care with or without the 9 
addition of our BET plus education sessions explaining its use. BET comprised an action 10 
plan, indicating when to seek medical help based on pictorial represented indications for 11 
antibiotic therapy, and four educational support sections. At baseline and after 12 months, 12 
patients completed the Self-Efficacy to Manage Chronic Disease Scale (SEMCD), St 13 
George’s Respiratory Questionnaire (SGRQ), EQ-5D-3L (to calculate Quality Adjusted Life 14 
Years (QALYs) and cost questionnaires. Qualitative data were obtained by focus groups. 15 
 16 
Results: The recruitment to the study was high (63% of eligible patients agreeing to 17 
participate) however completion rate was low (57%). BET had no effect on SEMCD (mean 18 
difference (0.14 (95% confidence interval (95%CI) -0.37 to 0.64), p=0.59) or SGRQ, 19 
exacerbation rates, overall cost to the NHS or QALYs. Most had developed their own 20 
techniques for monitoring their condition and they did not find BET useful as it was difficult 21 
to complete. Participant knowledge was good in both groups. 22 
 23 
Conclusion: The demand for patient support in bronchiectasis was high suggesting a clinical 24 
need. However, the BET did not improve self-efficacy, health related quality of life, costs or 25 
clinically relevant outcome measures. BET needs to be modified to be less onerous for users 26 
 3 
and implemented within a wider package of care. Further studies, particularly those 1 
evaluating people newly diagnosed with bronchiectasis, are required and should allow for 2 
50% withdrawal rate or utilise less burdensome outcome measures.  3 
 4 
Clinical trials registration: ISRCTN ISRCTN 18400127. Registered 24 June 2015. 5 
Retrospectively Registered 6 
 7 
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 4 
Background 1 
Bronchiectasis, a chronic lung disease characterised by chronic purulent sputum production, 2 
breathlessness and cough, is managed with airway clearance techniques, airway 3 
pharmacotherapy and appropriate use of antibiotics, along with patient education and 4 
disease monitoring(1). People with bronchiectasis often have impaired health related quality 5 
of life (HRQOL) (2); and can experience repeated exacerbations due to lung infection 6 
resulting in deterioration in symptoms and increased hospital bed days and costs(3). 7 
 8 
Living with bronchiectasis results in considerable burden for patients, therefore methods of 9 
improving patient centered care are required to improve patient empowerment(4).  Patient 10 
Self-Management Plans (PSMP) aim to do this and have been shown to improve health 11 
outcomes for adults with asthma(5) and to be cost-effective(6). Indeed the recent European 12 
Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) consensus 13 
statement about research prorities highlighted the need for studies to determine the 14 
effectiveness of PSMP in bronchiectasis(7). A recently published systematic review 15 
concluded that there was insufficient evidence to determine whether self-management 16 
interventions are beneficial for people with bronchiectasis(8). 17 
 18 
We developed a self-management intervention for bronchiectasis (the Bronchiectasis 19 
Empowerment Tool (BET)) which was based on British Thoracic Society Guidelines, patient 20 
consultation and available literature on the patient perspective and needs for bronchiectasis 21 
self-management(9). It contained a 1 page action plan (which advises on actions depending 22 
on different circumstances) consisting of 3 action points, as is recommended(10), embedded 23 
in a document with written information and was supported by one to one education.  24 
 25 
 5 
The study aimed to test whether, in people with bronchiectasis, the use of BET, compared 1 
to standard care, would improve self-efficacy using the Self-Efficacy to Manage Chronic 2 
Disease Scale (SEMCD)(11), as this is a fundamental aspect of self-managment(12). 3 
Secondary aims were to assess the effect of BET on HRQOL and disease-related 4 
knowledge and to determine whether it was cost effective. We also aimed to explore the 5 
participants’ acceptability of BET. 6 
 7 
METHODS 8 
Design 9 
This was a multi-centre parallel randomised controlled mixed-methods parallel study of BET 10 
in people with bronchiectasis over a 12 month period. Participants from six hospitals (one 11 
bronchiectasis specialist centre, four local hospitals with specialist respiratory nursing 12 
support and one community hospital) in East Anglia, UK were recruited from May 2013 to 13 
April 2015. The study was conducted in accordance with Good Clinical Practice and all 14 
participants gave written informed consent. It had ethical approval (13/SC/0140) and was 15 
registered on a trials database (ISRCTN 18400127).  16 
 17 
Participants 18 
Patients, of either gender, were included if they were older than 18 years, had a diagnosis 19 
of bronchiectasis confirmed on high resolution computed tomography (HRCT) and at least 20 
one exacerbation within the previous 12 months requiring treatment with antibiotics. Patients 21 
with cystic fibrosis or traction bronchiectasis, severe or uncontrolled co-morbid disease, 22 
impairment in cognitive functioning or did not speak English language were excluded. 23 
Patients currently using a written patient self-management plan or involved in the design of 24 
BET were also excluded. 25 
 26 
 6 
Randomisation 1 
Eligible participants were randomised to the intervention or control groups, after completion 2 
of the baseline assessments, on a 1:1 basis using a computer generated code created by 3 
the study statistician with stratification according to hospital centre and severity of disease 4 
(four or more exacerbations in the last 12 months versus less than four) with code 5 
concealment in sequential opaque envelopes. Treatment allocation was undertaken by an 6 
unblinded researcher. All eligible participants received the contemporaneous British Lung 7 
Foundation Bronchiectasis Patient Information Sheet and Bronchiectasis Patient 8 
Information Leaflet from the British Thoracic Society/Association of Chartered 9 
Physiotherapists Respiratory Care Guidelines (13).  10 
 11 
Intervention 12 
Participants randomised to the intervention group received the BET document plus 13 
education sessions about its use. BET is a 48 page A5 booklet and comprises an action 14 
plan, four educational support sections each with notepads to assist in keeping track of their 15 
health, and links to on-line resources. The action plan is based on the indications for 16 
antibiotic therapy from the BTS bronchiectasis guidelines (sputum purulence, sputum 17 
volume and cough/wheeze/breathlessness) and pictorially represents easily recognisable 18 
health changes indicating when to seek medical help, to minimise barriers of health literacy. 19 
The educational support sections comprise information about general health, sputum 20 
clearance techniques and medication. There is a section for recording each course of 21 
antibiotic and date of sputum microbiology.  22 
 23 
An un-blinded researcher (CB), previously a respiratory nurse, provided education about 24 
BET via four brief telephone conversations (lasting on average 10, 7, 5 and 2 minutes) 25 
delivered on consecutive days at the beginning of the study; these covered the use of the 26 
 7 
action plan and the information, monitoring and reference sections. Participants were given 1 
the opportunity to ask questions and to practice using the tool. Patients were provided with 2 
a contact number for information about the study and use of BET (but not for clinical queries). 3 
Participants’ healthcare providers were provided with brief information about BET in a letter. 4 
 5 
Control 6 
Participants within the control group received standard care whereby patients attended 7 
routine appointment and were guided on their management according to current practice as 8 
per the BTS bronchiectasis guidelines. 9 
 10 
Measurements 11 
Patients received the six item SEMCD to assess self-efficacy as it is a valid, responsive tool 12 
with high internal consistency in chronic disease, ranging between 1 and 10 with 10 scoring 13 
total confidence in managing disease(11) and used to evaluate self-management 14 
programmes(14); the St George’s Respiratory Questionnaire (SGRQ)(15) to assess disease 15 
HRQOL as it has been validated for use in bronchiectasis(16); the EuroQol-5D 3 level 16 
version (EQ-5D-3L)(17) to assess HRQOL; and cost questionnaires at baseline and every 17 
3 months by post in a reply paid envelope. The Lung Information Needs Questionnaire 18 
(LINQ)(18), which assesses knowledge and behaviour is validated in patients with chronic 19 
obstructive pulmonary disease but is easily transferable to bronchiectasis was completed at 20 
baseline and after 12 months. As no appropriate validated questionnaire existed which 21 
addressed the participants’ knowledge and confidence about bronchiectasis a new 22 
questionnaire was created in consultation with the research team and lay advisors was 23 
completed after12 months by participants.. Patients who failed to return the questionnaires 24 
were sent a reminder questionnaire by post. The number of exacerbations of 25 
 8 
bronchiectasis(19), medical contacts and sputum microbiology requests were obtained from 1 
cost questionnaires and hospital records.  2 
 3 
Two focus groups, comprising 4 participants each, purposively sampled to include patients 4 
with mild and severe disease from the intervention group, were facilitated by CB under 5 
supervision of AS (qualitative research expert) using a semi-structured interviewing 6 
technique, to explore participants’ perceptions of BET.  7 
 8 
Analysis 9 
The primary outcome was the change from baseline in SEMCD. A sample size of 154 10 
patients has 80% power to detect a treatment difference (two sided 5% significance) of 1 11 
unit (10% of maximum score) of the SEMCD with a standard deviation of 2.2 units(20). We 12 
expected a withdrawal of 30% based study in chronic obstructive pulmonary disease with 13 
similar questionnaire burden(21), and therefore 220 patients were entered into the study. All 14 
data were double entered and discrepancies resolved by re-examining the source data. 15 
LINQ was analysed using the LINQ Scoring Tool (www.linq.org.uk). The Bronchiectasis 16 
Aetiology Comorbidity Index was calculated from clinical data(22). 17 
 18 
The analysis was based on an intention-to-treat approach. Change from baseline for primary 19 
and secondary endpoints was compared between groups using a general linear model 20 
adjusted for baseline severity. Total exacerbations and unscheduled care were both 21 
compared using negative binomial regression and reported as the incidence rate ratio which 22 
is the ratio of the event rates between the study arms. Adjusted analyses were conducted 23 
by additionally including the baseline value in the model as a covariate, e.g. for the SEMCD 24 
outcome we adjusted for the baseline measure of SEMCD. Data are presented as mean 25 
and standard deviation. The analysis was undertaken using Stata 16.1/SE.  26 
 9 
 1 
Recordings of the focus groups were transcribed and a review of the data generated initial 2 
codes. Data from the focus groups were analysed in parallel to increase rigour(23). We used 3 
Microsoft Office Excel and computer assisted qualitative data analysis software (Nvivo11) 4 
to perform an inductive thematic analysis where patterns and clusters of linked data were 5 
organised into themes(24, 25).  In the results section we show selected quotes to illustrate 6 
the participants’ experience of using BET.  7 
 8 
Economic evaluation 9 
Costs were estimated from the perspective of the NHS. The intervention costs were for a 10 
specialist nurse to arrange and conduct telephone education sessions, who would require 2 11 
hour 1:1 training, and BET booklet printing. In the cost questionnaires, participants reported 12 
both hospital and community health visits. Unit costs were assigned to all items of resource 13 
use (£GBP ($USD) for the 2014-15 financial year)(26, 27).  14 
 15 
Responses to the EQ-5D-3L were converted into utility scores(28) using the UK York A1 16 
tariff(29). Quality Adjusted Life Year (QALY) scores were subsequently calculated using the 17 
area under the curve approach(30). Multiple imputation was performed to account for 18 
missing cost and outcome data(31). Regression analysis(32) was subsequently used to 19 
estimate the mean incremental cost (mean difference in cost) and effect (QALY gain) 20 
between the two groups and the incremental cost-effectiveness ratio (ICER)(33). The cost 21 
effectiveness acceptability curve (CEAC), which estimates the probability of the intervention 22 
being cost-effective(34), was estimated at a value of £20,000 ($26,400) per QALY. 23 
 24 
RESULTS 25 
 10 
The intention-to-treat analysis included 220 randomised patients, of which 155 (69%) were 1 
female, which represented 63.2% of eligible individuals (Figure 1). They had a mean 2 
(standard deviation) age of 66.9 (12.0) years, FEV1 1.84 (0.69) L, SEMCD 7.02 (2.0), total 3 
SGRQ 42.4 (19.1) and a median (inter quartile range) time from diagnosis of 5 (2 - 14) years.  4 
The two groups were well balanced at baseline and hence no adjustment to the analysis 5 
was required to account for baseline factors (Table 1). The withdrawal rate was higher than 6 
expected with only 127 individuals (57%) returning the primary outcome questionnaire at 12 7 
months.  There was no difference in the change in SEMCD between the two study arms. 8 
The data were very slightly negatively skewed, but re-analysis using the bootstrap with 1,000 9 
iterations gave similar results particularly for the adjusted analysis (unadjusted p=0.96, 10 
adjusted p=0.60) so that the results are not sensitive to the violation of the assumptions of 11 
the t-test. There were no significant differences between intervention and control for change 12 
in SGRQ, exacerbation rate, LINQ score or sputum microbiology requests (Table 2). In 13 
addition there were no differences between the intervention and control at any of the three 14 
month time points for any of the variables. Both groups were confident in managing their 15 
condition at the end of the study (Table 3). 16 
 17 
Within the focus groups three participants out of 8 had fully utilised the BET tool. Seven out 18 
of eight, felt the need for support with bronchiectasis, but not necessarily in the form of BET. 19 
Most participants of the focus group had already developed their own techniques for 20 
monitoring their condition. One of them said ‘A lot of the things in there I already knew, but 21 
not everybody would, particularly the newly diagnosed wouldn’t’. Another one said that  22 
 23 
‘…what I would do is make it slightly simpler, I felt that sometimes I was 24 
repeating things. When you are filling it in, you are not well at the time and that 25 
 11 
makes it more difficult. I think that if someone could have reviewed my progress 1 
with me and guided me it might have been even more successful’. 1105  2 
 3 
However, those that did use BET reported having gained a clearer and better insight into 4 
the presentation and duration of their symptoms.  5 
 6 
“Without that [BET] I would have been lost. Because I was able to take the BET 7 
booklet with me to appointments and let them know what worked effectively and 8 
what wasn’t for instance when I went to the hospital I was able to say Meropenem 9 
and Tobramycin IVs to Dr R.” 1056 10 
 11 
The aspect that was mentioned most was the improved interaction and 12 
communication with healthcare professionals and secondly the self-care behaviours 13 
e.g. sputum testing and airway clearance. Emerging themes ranged from impact of 14 
the disease on social interactions; embarrassment, change of role and isolation, to 15 
the challenges of taking antibiotics influenced by side-effects, media messages and 16 
the complexities of intravenous self-administration (see appendix).  An overarching 17 
theme was the need for informed guidance and support illustrated by the following 18 
extracts 19 
“From a personal basis not being able to pick up a phone and say to somebody 20 
do you think that it is alright? Do you think that I can do something to improve 21 
things? If you know someone who knows a lot about it that would be wonderful. 22 
A nurse to talk to.” 1044 23 
 24 
 12 
“It was nice as I mentioned earlier to speak to a GP who was knowledgeable 1 
and knew exactly what I was saying. I do remember it was a yippee moment. 2 
But sadly that person is leaving”. 1091 3 
 4 
“There is no easy flow of information or updates to patients, they get 5 
nothing]…[For a majority of my housebound patients they do not get regularly 6 
reviewed by either a GP or a hospital consultant.” 2001 7 
 8 
The intervention was estimated to be £40.11 ($52.95) per participant: 15 minutes per 9 
participant to arrange the phone calls, 24 minutes for the education sessions, £176 10 
($232.32) for staff training and £245 ($323.40) for printing BET. Table 4 summarizes the 11 
mean QALY scores. The mean incremental cost was estimated for the intervention group, 12 
compared to the control group, to be £355.94 ($469.85) (95% confidence interval (CI) –13 
£444.97 to £1156.85 (-$587.36 to $1527.04) and the mean QALY score to be 0.006 higher 14 
(95% CI –0.042 to 0.053). This resulted in an ICER of £64,223 ($84,774). According to the 15 
CEAC there was a 36.3% probability that the intervention was cost-effective at a λ of £20,000 16 
($26,400) per QALY. 17 
 18 
DISCUSSION 19 
 20 
We did not show that the use of BET had a beneficial effect in terms of self-efficacy, HRQOL 21 
or clinically relevant disease outcome measures such as exacerbations or hospitalisations 22 
or costs. The uptake into the study was high reflecting patients desire to be involved with 23 
and assist initiatives to increase their education and support for their condition. However, 24 
participants did not find the self-management tool to be valuable as, although the action plan 25 
was brief, overall BET was too onerous to complete and few participants used it. The 26 
 13 
participants did not feel more informed about their condition and there was no change in 1 
their behaviour. None of the participants were newly diagnosed and many had developed 2 
their own techniques to monitor and manage their disease. This was despite the involvement 3 
of patients with bronchiectasis in the development of BET although they were possibly self-4 
selected in terms of their enthusiasm for the intervention. 5 
 6 
Unfortunately the patient withdrawal was higher than we expected and therefore our study 7 
was underpowered. This may be due to the lack of study visits, and face-to-face contact with 8 
researchers, or to the burden of literacy represented by the intervention and patient reported 9 
outcome and cost measures. The low intensity nature of the study visits but relatively high 10 
questionnaire burden may have resulted in disengagement with the study. Also the BET tool 11 
was not evaluated within a larger process of care and it could not be modified by the clinical 12 
team or patient. It is likely that if the healthcare professionals involved had been regularly 13 
reviewing and updating the action plan or educational material or notepads contained within 14 
BET, it would have been used more. Although the separate elements of a care bundle need 15 
to be individually assessed(35), action plans are more effective if integrated within 16 
healthcare(36); and lack of review of asthma self-management plans by healthcare 17 
professionals leads to lack of interest by patients(37).  18 
 19 
The action plan in BET was accompanied by  brief written and one-to-one patient education 20 
as we envisaged that would be the case in clinical practice. This was delivered by phone as 21 
this was more convenient, permitted standardised training throughout a multi-centre study 22 
and was preferred by the patients. Many people in the focus groups liked the telephone 23 
education and indeed structured telephone support has been shown to be beneficial for 24 
people with chronic heart failure(38). However, a more intensive programme or one 25 
integrated within the practice and championed by healthcare providers may have had 26 
 14 
greater uptake and benefit(39). We did not include training on skills such as problem solving, 1 
decision-making, goal setting and emotional management. Diabetes standards suggest 2 
greater than 10 hours of support are required for implementation of self-management 3 
plans(40). 4 
 5 
We had broad inclusion criteria for this study, only requiring documented evidence of 6 
diagnosis and one exacerbation in the previous year, to maximise generalizability. However 7 
our participants had less impaired HRQOL compared to other trials(41) (but similar to 8 
observational studies(16)) and the majority of individuals felt confident about bronchiectasis 9 
in both groups at the end of the study. It is possible that the reason for lack of detectable 10 
benefit is that the patients had relatively mild disease of long duration (average more than a 11 
decade) and had already developed mechanisms for managing their disease so did not 12 
benefit from this alternative tool. Indeed, it was suggested in the focus groups that 13 
individuals with newly diagnosed disease would find the tool more beneficial but we did not 14 
purposively sample those with a good response for the focus groups 15 
 16 
Conclusion 17 
We have shown that BET did not improve outcomes. Many participants had mild disease, 18 
already developed self-management techniques and/or considered themselves confident 19 
with their condition. The telephone education was appreciated by participants and could be 20 
utilised to a greater extent in the future. BET should not be used as it stands but a simplified 21 
version should be evaluated in newly diagnosed patients, probably in the context of a wider 22 
care package with more intensive support. Recruitment into the study was high suggesting 23 
a clinical need but future studies should allow for up to 50% withdrawal rate or utilise less 24 
burdensome outcome measures, perhaps capturing patients ability to communicate with 25 
healthcare professionals or bronchiectasis specific HRQOL.  26 
 15 
 1 
  2 
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Table 1 Summary of baseline characteristics for all individuals 1 
 2 
Factor Control Intervention 
Age (years) 66.3 (13.4) 67.4 (10.5) 
Gender   
f 78 (70.3%) 73(67.0%) 
m 33 (29.7%) 36 (33.0%) 
Smoking status   
Current smoker 7 (6.5%) 1 (1.0%) 
Ex-smoker 45 (41.7%) 47 (44.8%) 
Never smoked 56 (51.9%) 57 (54.3%) 
FEV1 (L) 1.9 (0.8) 1.8 (0.6) 
%,  82.3 (25.5) 75.4 (21.7) 
FVC (L) 2.8 (0.9) 2.8 (0.9) 
%,  96.4 (20.9) 91.0 (21.5) 
Exacerbations   
>=4/year 40 (36.0%) 41 (37.6%) 
<4/year 71 (64.0%) 68 (62.4%) 
Exacerbations,  2.6 (3.0) 3.1 (3.0) 
SEMCD score,  6.8 (2.1) 7.2 (1.9) 
SGRQ total,  42.7 (21.1) 42.1 (17.0) 
SGRQ symptoms,  55.9 (25.3) 57.1 (23.2) 
SGRQ activity,  50.1 (27.8) 50.0 (23.0) 
SGRQ impact,  34.2 (19.9) 32.1 (15.8) 
 22 
Microbiology data (year 
before consent) 
  
Pseudomonas organism   
        None 64 (72.73) 70 (77.78) 
        One  12 (13.64) 11 (12.22) 
        Two or more 12 (13.64) 9 (10.00) 
Haemophilus organism   
        None 77 (87.50) 75 (83.33) 
        One  7 (7.95) 6 (6.67) 
        Two or more 4 (4.55) 9 (10.00) 
BACI score   
None or one 72 (64.9) 50 (45.9) 
Two or three 21 (18.9) 37 (33.9) 
Four or more 18 (16.2) 22 (20.2) 
Median, IQR 0 (0-3) 3 (0-3) 
LINQ score,  12.75 (2.50) 12.58 (2.40) 
  Disease knowledge 3.04 (0.73) 2.99 (0.70) 
  Medicines 2.34 (0.67) 2.37 (0.66) 
  Self-management 3.51 (1.53) 3.42 (1.60) 
  Smoking 0.14 (0.61) 0.00 (0.00) 
  Exercise 2.33 (1.06) 2.18 (1.13) 
Number of sputum 
samples 
1.82 (2.17) 2.25 (2.89) 
   
 1 
 23 
FEV1: Forced expiratory volume in 1 second, FVC: forced vital capacity, SEMCD: Self-1 
Efficacy to Manage Chronic Disease Scale, SGRQ: St George’s Respiratory 2 
Questionnaire, LINQ:  lung information needs questionnaire; BACI: Bronchiectasis 3 
Aetiology Comorbidity Index. Other than gender and smoking status, where data are 4 
represented as number and percentage, all data are represented as mean and standard 5 
deviation. 6 
 7 
 24 
 1 
Table 2 Change in outcome measures from baseline to 12 months follow-up. 2 
 3 
   Control  Intervention 
Mean difference  
p-value 
Mean difference 
(adusted for 
baseline values). 
(Intervention - 
Control) 
p-
value 
(Intervention - 
Control) 
 n Mean (SD) n Mean (SD) Mean (95% CI)  Mean (95% CI)  
SEMCD 67 -0.2 (1.6) 60 -0.2 (1.4) 0.01 (-0.51,0.53) 0.96 0.14 (-0.37,0.64) 0.59 
SGRQ                 
Total 61 1.3 (11.7) 54 1.6 (11.5) 0.27 (-3.98,4.52) 0.9 0.24 (-4.01,4.49) 0.91 
Activity 63 4.7 (17.8) 56 4.1 (14.3) -0.60 (-6.48,5.27) 0.84 -0.73 (-6.49,5.02) 0.8 
Impact 66 -1.0 (11.9) 59 0.1 (12.0) 1.21 (-2.95,5.37) 0.57 1.16 (-3.00,5.32) 0.59 
Symptoms 68 0.6 (18.8) 60 -1.0 (21.2) -1.54 (-8.48,5.39) 0.66 -1.47 (-8.03,5.09) 0.66 
LINQ 57 12.18 (2.73) 49 11.45 (2.19) -0.75 (-1.71,0.21) 0.124 -0.48 (-1.32,0.37) 0.265 
  Disease knowledge 50 -0.12 (0.92) 44 -0.14 (0.90)  0.894   
 25 
  Medicines 47 -0.15 (0.62) 40 -0.30 (0.72)  0.303   
  Self-management 47 -0.28 (1.36) 40 -0.10 (1.57)  0.854   
  Smoking 52 0 (0.0) 42 0 (0.0)  NA   
  Exercise 54 -0.07 (0.87) 44 0.18 (1.26)  0.238   
Sputum samples provided 93 1.48 (2.52) 95 2.09 (3.10) 1.54 (1.00,2.35) 0.048 1.29 (0.88,1.89) 0.197 
         
Exacerbations         
IRR  
  
Adjusted IRR (95% 
CI)   
  (Intervention / control) 
(95% CI)  
Exacerbations 0-12mths 34 3.6 (4.8) 21 6.3 (8.4) 1.64 (0.87,3.07) 0.12 1.57 (0.85,2.87) 0.15 
Hospital admissions or 
A&E attendances  
84 0.73 (1.12) 87 1.07 (1.84) 1.36 (0.85,2.18) 0.206 - - 
 1 
SEMCD: Self-Efficacy to Manage Chronic Disease Scale, SGRQ: St George’s Respiratory Questionnaire, LINQ:  lung information needs 2 
questionnaire, A&E: accident and emergency. Intention to treat analysis. IRR: incidence rate ratio (intervention/control) ASD: Standard 3 
Deviation. CI: confidence interval.   n:  number with data available for analysis. 4 
  5 
 26 
Table 3 Patients self-evaluation of their knowledge and confidence about bronchiectasis. 1 
  Control  Intervention  
 
Total 
number  
Number  
(percentage) 
Total 
number  
Number  
(percentage 
P  
I do NOT feel confident in deciding 
when I need treatment 
53 5 (9.4) 43 3 (7.0) 0.727* 
I know which bacteria grows in my 
sputum/phlegm 
48 18 (37.5) 41 15 (36.6) 0.929+ 
Sputum sample sent for testing… 50   41   0.111* 
  ..when I last had a flare up   25 (50)   28 (68.3)   
  ..within the last 6 months   3 (6)   0 (0)   
  ..within last 12 months   22 (44)   13 (31.7)   
Home supply of antibiotics 48   41   0.969* 
  I have a home supply & know when 
to use them 
  38 (79.2)   32 (78.1)   
  I have a home supply but I don’t 
feel confident starting them 
  3 (6.3)   2 (4.9)   
 27 
  I don’t have a home supply but 
would like to have some.  
  3 (6.3)   4 (9.8)   
  I don’t have a home supply but I 
don’t want the responsibility 
  4 (8.3)   3 (7.3)   
I feel confident that I understand 
my condition, how to get it treated 
when necessary and explaining it to 
family or friends. 
41 37 (90.2) 29 29 (96.6) 0.395* 
 1 
The analysis was conducted by * Chi-squared test and + Fisher's exact test. 2 
 3 
 4 
 28 
 1 
Table 4 – Quality adjusted life years score for intervention and control groups.  2 
 3 
  Control  Intervention 
 n mean (SD) n mean (SD) 
Baseline EQ-5D-
3L  
103 
0.709 
(0.297) 
101 
0.716 
(0.278) 
3 month EQ5D-3L  73 
0.724 
(0.285) 
60 
0.751 
(0.251) 
6 month EQ5D-3L  58 
0.704 
(0.300) 
48 
0.701 
(0.319) 
9 month EQ5D-3L  62 
0.655 
(0.323)  
53 
0.691 
(0.319) 
12 month EQ5D-
3L  
65 
0.737 
(0.270)  
58 
0.689 
(0.306) 
QALY  63 
0.723 
(0.263)  
57 
0.709 
(0.285) 
 29 
 1 
There was no difference in the QALY score between the two groups. n=Number for whom data were available; SD=standard deviation; 2 
QALY=Quality Adjusted Life Years over 12 months 3 
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Figure Legends 1 
Figure 1 Disposition of patients 2 
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